Frequently Asked Questions

Hemp-derived CBD (under 0.3% THC) is federally legal under the 2018 Farm Bill. However, the FDA hasn't established regulations for CBD in food, beverages, or supplements — creating a gray area. State laws vary. Check your state's current regulations before purchasing.

Full-spectrum CBD contains trace THC (under 0.3%) that can accumulate with regular use and potentially trigger a positive test. Broad-spectrum and isolate products should contain zero THC. If drug testing is a concern, use products with batch-specific COAs confirming non-detect THC levels.

Start with a full-spectrum tincture from a brand that publishes batch-specific COAs. Populum is our recommendation for CBD oil — CO2-extracted, lab-transparent, 30-day risk-free trial. Start at 10-25mg/day sublingual and adjust gradually. If you're curious about THC beverages too, Just Chill's craft tonics (4mg THC / 4mg CBD) are the gentlest entry point — the balanced CBD ratio keeps things calm and controlled. For the regulatory side of CBD — federal policy, state laws, and what's changing — Custom CBD Labs tracks the evolving legal landscape. For independent product reviews across CBD and cannabis categories, see The Green Reviews.

The only FDA-approved use is for rare forms of epilepsy (Epidiolex). Beyond that, research shows promise for anxiety, sleep, and pain management — but most studies are small and preliminary. CBD is not proven to cure any disease. Honest brands don't make disease claims.

Look for: (1) Cannabinoid potency — does CBD content match the label within 10%? (2) THC level — under 0.3% for legal compliance. (3) Contaminants — pesticides, heavy metals, residual solvents should all be 'pass' or 'not detected.' (4) Lab accreditation — the testing lab should be ISO 17025 accredited. (5) Batch-specific — the lot number should match your product.

CBD is generally well-tolerated, but it is not risk-free. Known side effects include drowsiness, dry mouth, diarrhea, reduced appetite, and fatigue — particularly at higher doses above 100mg/day. The most significant safety concern is drug interactions: CBD inhibits CYP3A4 and CYP2D6 liver enzymes, which can cause dangerous interactions with blood thinners like warfarin, certain heart medications, immunosuppressants, and some antidepressants (Nasrin et al., Drug Metabolism and Disposition, 2021). A 2019 FDA safety update also flagged potential liver injury at very high doses, based on Epidiolex clinical trial data. Always consult a healthcare provider before starting CBD, especially if you take any prescription medications. The lack of federal regulation means product quality varies enormously — contaminated or mislabeled products pose additional risks beyond CBD itself.

The FDA strongly advises against CBD use during pregnancy and breastfeeding. Cannabinoids cross the placental barrier and have been detected in breast milk. There is insufficient safety data to establish any safe dose for pregnant or nursing women. For children, the only FDA-approved CBD use is Epidiolex for rare seizure disorders (Lennox-Gastaut and Dravet syndromes), prescribed and monitored by a physician. Over-the-counter CBD products should not be given to children without explicit medical guidance. This is a caution endorsed by the American Academy of Pediatrics.

At standard supplement doses (10-50mg/day), liver injury is unlikely in healthy adults. However, the FDA flagged hepatotoxicity as a potential risk based on Epidiolex clinical trials, where patients received 10-20mg/kg/day — far exceeding typical consumer doses. A 2019 University of Arkansas study in mice found that very high CBD doses caused liver toxicity markers comparable to acetaminophen overdose (Molecules, 2019). The limitation of that study is the extreme dosing. At normal consumer doses, liver risk appears low, but anyone with existing liver conditions or taking hepatotoxic medications should consult a doctor before using CBD. Periodic liver function monitoring is recommended for heavy users.

The biggest downside of the unregulated CBD market is inconsistency. A landmark 2017 JAMA study found that 26% of products contained less CBD than labeled, 43% contained more, and 21% contained detectable THC not listed on the label. Without FDA oversight, consumers face risks including: contamination with pesticides, heavy metals, or residual solvents from extraction; mislabeled CBD content; undisclosed THC that could trigger drug test failures; and disease claims that have no scientific basis. The safety concern is not CBD itself — it is the lack of manufacturing standards and quality control. This is why third-party COAs from ISO 17025-accredited labs are the single most important consumer protection tool. Products without accessible, batch-specific COAs should be avoided entirely.